US Food and Drug Administration approvals continued at breakneck pace with 12 new molecular and biological entities. These included Roche's long-anticipated antibody-drug conjugate Kadcyla and Janssen's first-in-class sodium glucose type 2 transporter Invokana. The quarter was not without disappointment, however; in particular, Affymax recalled its recently approved erythropoietin mimetic Omontys.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline: 1Q13. Nat Biotechnol 31, 482 (2013). https://doi.org/10.1038/nbt.2607
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2607